Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement
10.3760/cma.j.issn.0253-2727.2020.11.003
- VernacularTitle:CCLG-ALL-2008方案治疗ETV6-RUNX1融合基因阳性儿童急性淋巴细胞白血病：单中心长期随访结果
- Author:
Fang LIU
1
;
Xiaojuan CHEN
;
Ye GUO
;
Wenyu YANG
;
Xia CHEN
;
Xiaoyan ZHANG
;
Ranran ZHANG
;
Yuanyuan REN
;
Xiaofan ZHU
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所）、实验血液学国家重点实验室、国家血液系统疾病临床医学研究中心
- Keywords:
Leukemia, lymphoblastic, acute;
Pediatric;
ETV6-RUNX1 rearrangement;
CCLG-ALL-2008 protocol;
Prognosis
- From:
Chinese Journal of Hematology
2020;41(11):896-902
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the predictive role of ETV6-RUNX1 fusion gene in protocol CCLG-ALL-2008 as well as identify the prognostic factors that influence the outcome of ALL with ETV6-RUNX1 fusion gene.Methods:One hundred and seventy-eight patients newly diagnosed with pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement from April 2008 to April 2015 were enrolled in CCLG-ALL-2008. The follow up period ended in July 2018; we performed retrospective analyses of their data to determine the efficacy of the regimen and the prognostic factors.Results:The median age of the study population (178 pediatric patients) , including 100 boys and 78 girls was 4 (1-13) y, and the median white blood cell count at diagnosis was 9.46 (1.25-239.83) ×10 9/L. Three patients died, and 1 was lost to follow up by the end of the first induction chemotherapy, resulting in an induced remission rate of 97.8% (174/178) . The cumulative incidence of relapse was 15.9% with a median follow up of 73.5 mon. Total 83.3% of the relapse cases were those of isolated bone marrow relapse, while 79.2% of the cases were those of late relapse. The median interval time between relapse and first complete remission was 35.5 mon (range, 1-62 months) . One of the 5 patients with early recurrence and 7 of the 19 with late recurrence cases survived. The 5-year-OS and 5-year-EFS of ETV6-RUNX1 positive children was (89.4±2.4) % and (82.1±6.9) %, respectively. The estimated 10-year-OS and 10-year-EFS of ETV6-RUNX1 positive children was (88.6±2.5) % and (77.3±4.0) %, respectively. The Kaplan-Meier method and Log-rank test were used to estimate and compare the survival. Univariate statistical analysis showed that poor prognostic factors that influenced survival included central nervous system state 2 at diagnosis, poor prednisone response, high risk, gene positivity after induction chemotherapy, as well as MRD positivity and gene positivity at the 12 th week. In the multivariate analysis, only the central nervous system state 2 at diagnosis and MRD positivity at the 12 th week were associated with the outcome. Conclusion:ETV6-RUNX1-positive ALL is a subgroup with a favorable prognosis as per the CCLG-ALL-2008 protocol. Patients with ETV6-RUNX1 should be given more intensive therapy, including hematopoietic stem cell transplantation when they are CNS2 at diagnosis or have high level of MRD at the 12 th week after treatment.
